Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
275 stopped studies mapped to Malignant Urinary Tract Neoplasm and descendants · 93% state a reason
Over the 275 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06290687 | Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative… | Phase 2 | withdrawn | Mar 4, 2024 | Case Comprehensive Cancer Center | PI left institution | Investigator |
| NCT04047693 | Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma | Phase 2 | terminated | Aug 7, 2019 | Pusan National University Yangsan Hospital | Poor accrual due to increased use of alternative neoadjuvant treatment options. | Enrollment / accrual |
| NCT05014139 | A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle… | Phase 1 | terminated | Aug 20, 2021 | Astellas Pharma Global Development, Inc. | Trial was discontinued for strategic reasons. Decision was not based on safety concerns, futility,… | Safety / toxicity |
| NCT07414992 | A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With… | Phase 2 | withdrawn | Feb 17, 2026 | Memorial Sloan Kettering Cancer Center | The sponsor is no longer supporting the trial because they are no longer interested in studying the… | Other (stated, no rule matched) |
| NCT02625961 | Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in… | Phase 2 | terminated | Dec 9, 2015 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT03185468 | Intervention of Bladder Cancer by CAR-T | Phase 1 / Phase 2 | terminated | Jun 14, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT02769962 | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With… | Phase 1 / Phase 2 | terminated | May 12, 2016 | National Cancer Institute (NCI) | Accrual and drug manufacturing and supply were discontinued in 2025. | Drug supply |
| NCT03869190 | Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and… | Phase 1 / Phase 2 | terminated | Mar 11, 2019 | Hoffmann-La Roche | Study was closed early as the sponsor decided not to continue development of certain treatment… | Sponsor / business decision |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With… | Phase 1 / Phase 2 | terminated | Sep 5, 2023 | Evopoint Biosciences Inc. | Strategic decision by Sponsor. | Sponsor / business decision |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Dec 15, 2023 | Genmab | Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk… | Other (stated, no rule matched) |
| NCT05714826 | Comprehensive Optimization At-time of Radical Cystectomy Intervention(COARC) | N/A | withdrawn | Feb 6, 2023 | University of Texas Southwestern Medical Center | Recruitment efforts had begun; however, no participants were enrolled, and the trial had been on a… | Enrollment / accrual |
| NCT02106572 | Therapeutic Instillation of Mistletoe(TIM) | Phase 3 | terminated | Apr 8, 2014 | Abnoba Gmbh | The study was terminated because the required number of patients cannot be reached in the… | Safety / toxicity |
| NCT02316548 | Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating… | Phase 2 | terminated | Dec 15, 2014 | NRG Oncology | Trial will not meet CTEP Early Phase Trial Slow Accrual Guidelines | Enrollment / accrual |
| NCT03324282 | First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder…(GCISAVE) | Phase 2 | terminated | Oct 27, 2017 | University Hospital, Bordeaux | ANSM's refusal to validate ATU requests for avelumab in bladder cancer, Decrease in recruitment,… | Enrollment / accrual |
| NCT07551544 | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed… | Phase 3 | withdrawn | Apr 27, 2026 | ImmunityBio, Inc. | Sponsor decision | Sponsor / business decision |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in… | Phase 1 | terminated | Mar 13, 2012 | M.D. Anderson Cancer Center | \< 75 % participation | Other (stated, no rule matched) |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced… | Phase 1 / Phase 2 | terminated | May 26, 2021 | M.D. Anderson Cancer Center | PI requested. | Other (stated, no rule matched) |
| NCT05581589 | Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial… | Phase 2 | terminated | Oct 14, 2022 | University of Washington | Study closed to accrual before meeting accrual goal due to major enrollment challenges based on the… | Enrollment / accrual |
| NCT05700227 | Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for…(ARTIA-Bladder) | N/A | terminated | Jan 26, 2023 | Varian, a Siemens Healthineers Company | Low enrollment | Enrollment / accrual |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | Phase 1 | terminated | May 17, 2023 | Aurigene Discovery Technologies Limited | Patient recruitment problems | Enrollment / accrual |
| NCT02143804 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade…(exBOND) | Phase 2 | withdrawn | May 21, 2014 | CG Oncology, Inc. | Change in trial design | Other (stated, no rule matched) |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People… | Phase 1 | terminated | Aug 30, 2024 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT03652298 | Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative…(NeuroPrevPTSD) | Phase 2 | terminated | Aug 29, 2018 | Centre Oscar Lambret | Lack of recruitment and of study staff | Enrollment / accrual |
| NCT06026332 | ADSTILADRIN Early Utilization and Outcomes in the Real World Setting(ABLE-41) | — | terminated | Sep 7, 2023 | Ferring Pharmaceuticals | An internal audit identified major inconsistencies and missing data in key registry fields,… | Other (stated, no rule matched) |
| NCT04856189 | Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or… | Phase 1 / Phase 2 | terminated | Apr 23, 2021 | Mamta Parikh | Poor accrual. | Enrollment / accrual |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and…(NIRADO) | Phase 2 | terminated | Mar 3, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Abandon of the partner, GSK | Other (stated, no rule matched) |
| NCT04412070 | Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in…(ALU) | — | terminated | Jun 2, 2020 | Hopital Foch | The target enrollment was not reached at the end of recrutement period. The presence of a… | Enrollment / accrual |
| NCT04003610 | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial… | Phase 2 | terminated | Jul 1, 2019 | Incyte Corporation | The reason this study was terminated was due to a business decision. There were no safety concerns… | Safety / toxicity |
| NCT03747419 | Avelumab and Radiation in Muscle-Invasive Bladder Cancer | Phase 2 | terminated | Nov 20, 2018 | Dana-Farber Cancer Institute | In agreement with the drug sponsor and the institution, the trial has been terminated due to slow… | Enrollment / accrual |
| NCT04586244 | An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or…(Optimus) | Phase 2 | terminated | Oct 14, 2020 | Incyte Corporation | Business Decision. No safety concerns contributed to this decision. | Safety / toxicity |
| NCT05564416 | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With… | Phase 2 | withdrawn | Oct 3, 2022 | National Cancer Institute (NCI) | Feasibility issues | Other (stated, no rule matched) |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT01495676 | A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for…(GETUGV04) | N/A | terminated | Dec 20, 2011 | Institut du Cancer de Montpellier - Val d'Aurelle | not stated | Not stated |
| NCT01382706 | Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | Phase 2 | terminated | Jun 27, 2011 | University of Southern California | Trial not progressing toward scientific goals | Other (stated, no rule matched) |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Phase 2 | terminated | Aug 2, 2021 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT01563796 | Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer | — | terminated | Mar 27, 2012 | Medical Diagnostic Laboratories, LLC | Business decision made not to pursue malignant disease diagnostic devices | Sponsor / business decision |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced… | Phase 1 | terminated | Feb 29, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT04887831 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer…(PRESERVE3) | Phase 2 | terminated | May 14, 2021 | G1 Therapeutics, Inc. | Sponsor no longer pursuing trilaciclib for the indication. | Other (stated, no rule matched) |
| NCT04936230 | Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer | Phase 2 | terminated | Jun 23, 2021 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT05248789 | OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer | Phase 2 | terminated | Feb 21, 2022 | Binhui Biopharmaceutical Co., Ltd. | Strategy adjustment | Sponsor / business decision |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT05687721 | Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer | Phase 1 / Phase 2 | withdrawn | Jan 18, 2023 | VA Office of Research and Development | The study drug is not available. | Other (stated, no rule matched) |
| NCT06421311 | Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With…(URADJ) | — | terminated | May 20, 2024 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT05242822 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or… | Phase 1 | terminated | Feb 16, 2022 | Kinnate Biopharma | Due to a change in the Sponsor's corporate strategy the study was terminated early by the Sponsor… | Enrollment / accrual |
| NCT05819827 | Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma… | — | terminated | Apr 19, 2023 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT02122172 | Afatinib in Advanced Refractory Urothelial Cancer | Phase 2 | terminated | Apr 24, 2014 | University of Chicago | Unable to meet accrual goal after several years | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials